NOVO Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NOVO, and when can generic versions of NOVO drugs launch?
NOVO has eleven approved drugs.
There are fifty-seven US patents protecting NOVO drugs.
There are four hundred and forty-two patent family members on NOVO drugs in forty countries and one hundred and nineteen supplementary protection certificates in seventeen countries.
Drugs and US Patents for NOVO
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-003 | Mar 28, 2022 | RX | Yes | Yes | 7,762,994 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-005 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Novo | RYBELSUS | semaglutide | TABLET;ORAL | 213051-002 | Sep 20, 2019 | RX | Yes | No | 10,278,923 | ⤷ Sign Up | ⤷ Sign Up | ||||
Novo | SAXENDA | liraglutide | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | 9,775,953*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Novo | RYBELSUS | semaglutide | TABLET;ORAL | 213051-001 | Sep 20, 2019 | RX | Yes | No | 9,278,123 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NOVO
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novo Nordisk Inc | PRANDIMET | metformin hydrochloride; repaglinide | TABLET;ORAL | 022386-001 | Jun 23, 2008 | 6,677,358 | ⤷ Sign Up |
Novo Nordisk Inc | PRANDIMET | metformin hydrochloride; repaglinide | TABLET;ORAL | 022386-002 | Jun 23, 2008 | 6,677,358 | ⤷ Sign Up |
Novo | SAXENDA | liraglutide | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | 6,458,924 | ⤷ Sign Up |
Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-002 | Apr 9, 2019 | 8,579,869 | ⤷ Sign Up |
Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RE43834 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NOVO drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 1 mg/500 mg and 2 mg/500 mg | ➤ Subscribe | 2009-04-09 |
➤ Subscribe | Injection | 18 mg/3 mL prefilled syringe | ➤ Subscribe | 2016-12-12 |
➤ Subscribe | Vaginal Tablets | 10 mcg | ➤ Subscribe | 2013-01-02 |
International Patents for NOVO Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 182613 | ⤷ Sign Up |
Spain | 2351778 | ⤷ Sign Up |
Australia | 2013286177 | ⤷ Sign Up |
Russian Federation | 2388498 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2006079481 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NOVO Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2498758 | 122020000018 | Germany | ⤷ Sign Up | PRODUCT NAME: METFORMIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; SAXAGLIPTIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; DAPAGLIFLOZIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1401 20191111 |
2498758 | 16/2020 | Austria | ⤷ Sign Up | PRODUCT NAME: METFORMIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; SAXAGLIPTIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; DAPAGLIFLOZIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1401 (MITTEILUNG) 20191113 |
2498758 | CR 2020 00017 | Denmark | ⤷ Sign Up | PRODUCT NAME: METFORMIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; SAXAGLIPTIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SOLVAT DERAF; REG. NO/DATE: EU/1/19/1401 20191113 |
1453521 | C201630040 | Spain | ⤷ Sign Up | PRODUCT NAME: ETINILESTRADIOL Y MEZCLA DE LEVONORGESTREL Y ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: 80340; DATE OF AUTHORISATION: 20160122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150211 |
0944648 | 09C0054 | France | ⤷ Sign Up | PRODUCT NAME: LIRAGLUTIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/529/001 DU 20090630; REGISTRATION NO/DATE AT EEC: EU/1/09/529/001 DU 20090630 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.